COVID antiviral eligibility: navigating the maze

Press/Media: Expert Comment

Description

Article describing the discrepancies in appropriate use criteria for COVID-19 antiviral therapies

Subject

Pharmaceutical Benefits System

National COVID-19 Clinical Evidence Taskforce

Antiviral

COVID-19

Period13 Jun 2022

Media contributions

1

Media contributions